Does isolated commercial neural-antibody panel positivity diagnose autoimmune encephalitis?

Autoimmune encephalitis (AE) is a syndrome-level diagnosis, not simply a laboratory result. Neuronal surface antibodies can be pathogenic in defined diseases, but their interpretation requires alignment among phenotype, objective findings, specimen, assay, and antibody-specific biology.

Mechanistic and clinical evidence

• Patient-derived anti-NMDAR IgG can cross-link GluN1-containing receptors, causing receptor internalization with reduced synaptic NMDAR currents and synaptic plasticity. Experimental models link these changes to memory impairment and psychosis-like behavioral changes.
• GABA-A receptor antibodies can inhibit receptor currents and reduce synaptic/extrasynaptic receptor availability, a mechanism consistent with increased neuronal excitability; associated clinical syndromes can include hallucinations and cognitive or behavioral change.
• CASPR2 antibodies may disrupt CASPR2–contactin-2 interactions and Kv1-channel organization, altering channel expression and excitability. Cognitive impairment may occur, though the mechanistic-to-clinical link is less completely reproduced than for NMDAR disease.
• These findings apply to defined antibody-mediated encephalitides and do not make neuronal-surface antibodies a general explanation for primary psychiatric symptoms.

Diagnostic interpretation and confirmation

• A commercial neural-antibody panel result alone is not diagnostic. Clinical relevance depends on the pretest probability from a compatible subacute presentation, antibody level, assay characteristics, and whether serum, CSF, or both were tested.
• In one clinical series, tissue-based immunohistochemistry confirmation increased positive predictive value from 69.7% to 97.1% for NMDAR and from 71.7% to 94.3% for CASPR2.
• AE assessment generally requires subacute memory, mental-status, or psychiatric change (within 3 months), at least one supportive objective feature—new focal findings, unexplained seizures, CSF pleocytosis, or suggestive MRI—and reasonable exclusion of alternatives.
• Unexpected, weak, discordant, or serum-only results warrant paired serum/CSF testing and independent antigen-specific or tissue-based confirmation. CSF is essential in suspected NMDAR encephalitis, whereas serum may be more sensitive for LGI1/CASPR2.

Bottom line

• Neuronal surface antibodies can directly disturb receptor/channel signaling and contribute to cognitive or neuropsychiatric syndromes, but isolated commercial positivity must be clinically contextualized and confirmed before attributing symptoms to AE.